Sudarshan Pharma Q1 FY27 Results: Net Profit Reaches ₹58.6 Million

MUMBAI, India — Mumbai-headquartered speciality chemicals and pharmaceutical company Sudarshan Pharma Industries Limited announced its consolidated financial results for the first quarter ended June 30, 2026, reporting a consolidated revenue from operations of ₹1.74 billion ($20.9 million). The figure highlights a robust 20.07% expansion compared to the ₹1.45 billion recorded in the same period last fiscal year.

The regulatory filings submitted to the BSE Limited reveal that the group’s consolidated net profit for the quarter stood at ₹58.6 million. Although earnings per share reflected sequential operational changes, the board outlined crucial strategic decisions during the quarterly meeting, including overseas expansions, capital fundraising via foreign currency bonds, and plant rationalization.

Financial Overview and Detailed Earnings Breakdown

The company's performance in the first quarter of fiscal year 2027 reflects growth across key operational areas alongside strategic adjustments. Consolidated total income reached ₹1.76 billion, up from ₹1.46 billion in Q1 FY26. Expenses rose in tandem with market expansion, totaling ₹1.68 billion compared to ₹1.41 billion in the prior-year quarter.

Standalone revenue from operations for the quarter stood at ₹1.66 billion against ₹1.42 billion reported in Q1 FY26. Standalone net profit climbed to ₹60.42 million compared to ₹37.33 million in the corresponding quarter of the previous year.

Strategic Restructuring and Global Operations

During the quarter ended June 30, 2026, the company decided to officially discontinue operations at its Palghar manufacturing facility. Management confirmed that the decision was finalized after examining the unit's operational contribution, aiming to curb ongoing losses, rationalize fixed costs, and direct resources toward high-yield operations.

On the international front, the board confirmed the incorporation of "Sudarshan Industries Inc." in the United States on June 5, 2026, as a wholly owned subsidiary to handle global trade, imports, exports, and distribution of Active Pharmaceutical Ingredients (APIs) and specialty chemical lines. Additionally, the firm recovered ₹46.8 million out of an awarded legal settlement of UAE Dirham 4.03 million from Dubai Court proceedings against Regans International DMCC.

Corporate Capital Structuring

Sudarshan Pharma Industries executed key board approvals to enhance its financial flexibility:

• FCCB Allotment: Issued U.S. $10 million 8.00% senior unsecured Foreign Currency Convertible Bonds due 2029 out of a broader board-approved umbrella plan to raise up to ₹15 billion through convertible instruments.

• Warrant Conversions: Converted 900,000 warrants into 9,000,000 equity shares to company promoters at an issue price of ₹16.98 per share, increasing paid-up equity capital to ₹249.66 million.

Official Sources Section

According to official filings submitted by Company Secretary Nirav Shah and Joint Managing Director Sachin Mehta to the BSE Listing Department pursuant to Regulation 33 of SEBI (LODR) Regulations, 2015, the financial outcomes were reviewed by the Audit Committee and approved by the Board of Directors on August 12, 2026. The audit report issued by statutory auditors NGST & Associates contained unmodified review findings.

Quote Section

According to officials in the corporate declaration:

"The decision to discontinue manufacturing operations at the Palghar unit was taken after evaluating the unit's operating performance and contribution. The closure will help rationalize fixed costs, minimize further losses, and enable management to focus resources on sustainable, profitable operations."

Why It Matters

The shift toward global trading subsidiaries and operational consolidation reflects a broader pivot toward capital efficiency. Investors and retail market participants gain clearer capital structure transparency following promoter warrant conversions and structured foreign currency bond offerings, which provide strategic liquidity for pharmaceutical intermediate distribution.

Key Facts at a Glance

• Consolidated Revenue: ₹1.74 billion in Q1 FY27, up 20.07% Year-on-Year.

• Consolidated Net Profit: Reported at ₹58.6 million for the June quarter.

• Manufacturing Update: Operations at the Palghar unit have been formally discontinued to rationalize costs.

• US Expansion: Established US subsidiary, Sudarshan Industries Inc., effective June 5, 2026.

• Capital Raise: Successfully allocated $10 million in 8% Foreign Currency Convertible Bonds (FCCBs) due 2029.

FAQ Section

What was Sudarshan Pharma's consolidated revenue for Q1 FY27? Sudarshan Pharma reported consolidated operational revenue of ₹1.74 billion for the quarter ended June 30, 2026.

Why did Sudarshan Pharma close its Palghar manufacturing plant? The unit was shut down to minimize operational losses, rationalize fixed costs, and reallocate corporate capital toward higher-margin commercial activities.

Did Sudarshan Pharma raise additional equity or debt during the quarter? Yes, the company allocated $10 million in FCCBs due 2029 and converted promoter warrants into 9,00,00,00 equity shares.

Source: Official regulatory disclosures filed under BSE Scrip Code 543828 by the Ministry of Corporate Affairs and BSE India Corporate Announcements Desk.